The Pharmaceutical Market: Iraq
OVERVIEW OF THE PHARMACEUTICAL
MARKET IN IRAQ
Years of underinvestment have taken their
toll on the Iraqi healthcare market, as have international sanctions
and deterioration of healthcare infrastructure due to war. Still an
unpopular figure on the international market, Iraq\'s trade partners
are few and far between - although Iraq does have a strong bargaining
chip: its oil resources. Healthcare facilities are gradually
improving, with plans for new hospitals such as two specialist
hospitals planned in partnership with Iran\'sRed Crescent
organisation. But access to funding is limited, import and exports
are restricted, and the country has a severe shortage of trained
medical professionals. As such, it is of little surprise that there
are few distinctions in the market between OTC and prescription
drugs, and counterfeit medicines are rife.
Headline Expenditure Projections
- Pharmaceuticals : IQD1,239bn (US$1.06mn) in 2011 to IQD1,476bn (US$1.26bn) in 2012; +19.1% in local currency and +19.0% in US dollar terms. Forecast broadly unchanged from Q 4 12.
- Healthcare: IQD9,439bn (US$8.07bn) in 2011 to IQD11,532bn (US$9.86bn) in 2012; +22.1% in local currency and +22.1% in US dollar terms. Forecast broadly unchanged from Q4 12.
- Medical devices: IQD407.35bn (US$348mn) in 2011 to IQD483.89bn (US$414mn) in 2012; +18.8% in local currency and +18.7% US dollar terms. Forecast broadly unchanged from Q 4 12.
To
Browse a Full Report with TOC @
http://www.researchmoz.us/the-pharmaceutical-market-iraq-report.html
Risk/Reward
Rating
In
our latest Pharmaceuticals Risk/Reward Ratings (RRRs), Iraq was 13th
out of the 30 markets surveyed in the Middle East and Africa (MEA)
region, the same ranking as Q412. The country\'s composite score was
stable at 46.7 out of the maximum 100 points. However, Iraq\'s risks
remain high due to the country\'s political and security instability,
which will continue to pose significant downward risks to our
forecasts.
Competitive
Landscape
The
competitive landscape section provides comparative company analyses
and rankings by US$ sales and % share of total sales - for the total
pharmaceutical sector, as well as the OTC, generics, and distribution
sub-sectors.
Table
of Contents
BMI
Industry View7
SWOT9
Political11
Economic12
Business
Environment13
Industry
Forecast14
Pharmaceutical
Market Forecast14
Table:
Pharmaceutical Sales Indicators 2009-201715
Healthcare
Market Forecast16
Table:
Healthcare Expenditure Indicators 2009-201718
Table:
Healthcare Governmental Indicators 2009-201719
Table:
Healthcare Private Indicators 2009-201719
Economic
Analysis20
Private
Consumption Outlook21
Fixed
Investment Outlook22
For More Information Kindly Contact:
ResearchMoz
Mr.
Nachiket Ghumare,
Tel:
866-997-4948
(Us-Canada
Toll Free)
Tel:
+1-518-621-2074
Website:
http://www.researchmoz.us
Comments
Post a Comment